China Biotech Services Achieves First Beam Emission with BNCT Device
China Biotech Services Holdings Ltd. announced that its NeuCure® neutron irradiation system, the core device for boron neutron capture therapy (BNCT) at the Pengbo (Hainan) BNCT Hospital, has successfully performed its first beam emission. This milestone marks the transition of the project from equipment installation to the clinical commissioning phase, verifying that the system's core components meet design specifications. The company stated that the BNCT system is currently the only one in the world with a formal medical device registration certificate and is ready for regular clinical treatment, with related services expected to commence in the first quarter of 2026. These results have just been achieved and announced by the company; they have not yet been presented elsewhere.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Biotech Services Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251125-11928119), on November 25, 2025, and is solely responsible for the information contained therein.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。